A great choice for COVID-19 gains

PFIZER INC. $37 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $207.2 billion; Price-to-sales ratio: 4.1; Dividend yield: 4.1%; TSINetwork Rating: Above Average; www.pfizer.com) saw its revenue in the first quarter of 2020 fall 8.3%,… Read More

You’ll profit from Pfizer’s new focus

Under a new long-term strategy, Pfizer is concentrating on what it does best: developing new patented drugs that generate strong returns for its shareholders.
As part of that plan, the company is merging its over-the-counter and generic drugs businesses with those of other pharmaceutical firms to… Read More